Our patent-pending Curasorb alloy is the first absorbable metal implant material to match titanium’s performance and deliver optimal safe absorption. We have specially engineered this technology to offer the entire performance package that surgeons desire for implant hardware: the same implantation technique, cost and reliability as traditional metal implants, plus safe absorption that avoids inflammatory reactions and restores natural physiology to patients without removal surgeries.

Curasorb is a high-performance, non-coated implant material, which allows for development of a robust product portfolio with full plating systems that can address broader market applications for hard and soft tissue fixation.

Advanced Magnesium Alloy Technology

The Curasorb Difference

  • ✺

    Proprietary Intellectual Property with two patents pending;
    100% ownership by Entirety Biomedical

  • ✺

    Platform technology that can be tailored to a variety of market applications and anatomies

  • ✺

    Prototypes created and tested in multiple designs with highly favorable surgeon response

  • ✺

    Positive bench and comparator data; preclinical results with strong bone-to-implant contact, absorption control

  • ✺

    External validation of market approach through in-depth customer discovery and hands-on surgeon evaluations

  • ✺

    Domestic supply chain; partner with exclusive US source of magnesium- a major competitive advantage

Product Development Market Applications

Ortho Extremities

Maxillofacial

Sports Medicine

Technology FAQs

  • Our Curasorb magnesium alloy is the first high performance metal absorbable implant material able to replace titanium in multiple indications, enabled by adjustable/optimized absorption that promotes bone healing before gradually and safely restoring the implant site to its natural physiology. This patent-pending alloy backed by trade-secret is made to be plug-and-play for titanium implants, matching the designs, performance, and simple implantation techniques for easier surgeon adoption, with the added benefit of a unique absorption process that is well controlled for reliable and safe bone fusion to enable superior patient outcomes. 

  • The Curasorb technology meets surgical performance requirements where resorbable polymer technology is incapable due to its lack of strength and rigidity. Unlike polymers- Curasorb implants look and feel just like traditional metal implants. Polymers have weaker mechanical properties, cost more, and require additional steps/surgeon training for the surgical procedure, with more risk of inflammatory response.

  • Magnesium alloys were introduced more than a decade ago to resolve the strength issues of polymers. However, early attempts at Mg alloys

  • Unlike traditional metal, Magnesium can stimulate bone formation, has mechanical properties closer to natural bone, and degrades naturally in the body over time , eliminating the need for a second implant removal surgery

  • Yes! Curasorb will be covered under existing US reimbursement codes for common ortho fixation procedures.

  • Permanent metal implants are today’s standard in bone fixation surgery, leaving patients vulnerable to complications, infections and chronic pain. Implant hardware removal surgeries are challenging procedures that introduce additional risks, costs and trauma for patients and the healthcare system, thus they are largely avoided, forcing patients to manage lifelong complications. Our easy-to-use, reliable and absorbable implant technology can solve this problem as a superior alternative to existing absorbable/permanent products. 

  • Curasorb is designed as a highly versatile platform to address broader markets with its load-bearing capabilities and unique adjustable absorption profile to meet varying user need across various implant applications and indications. Curasorb implants will improve patient outcomes, lower cost of care and drastically simplify the healing journey. We achieve this by restoring patients to their natural physiology without hardware removal surgery.

  • Entirety Biomedical has 100% ownership of all IP for its alloy